Complex prosthetic joint infections due to carbapenemase-producing Klebsiella pneumoniae: A unique challenge in the era of untreatable infections

International Journal of Infectious Diseases

Volumn 25, Issue , 2014, Pages 73-78

  de Sanctis, Jorgelina ^a,b,c   Teixeira, Lucileia ^a,b,c   van Duin, David ^a,b,c   Odio, Camila ^d   Hall, Geraldine ^a,b,c   Tomford, J Walton ^a,b,c   Perez, Federico ^e,f   Rudin, Susan D ^e   Bonomo, Robert A ^e,f   Barsoum, Wael K ^b   Joyce, Michael ^b   Krebs, Viktor ^b   Schmitt, Steven ^a,b,c  

^a SPECTRUM HEALTH   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^f CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carbapenem resistant Enterobacteriaceae; Carbapenem resistant Klebsiella pneumoniae; Colistin; K. pneumoniae carbapenemase (KPC); Multidrug resistant organisms; Prosthetic joint infection

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CARBAPENEMASE; CEFTAZIDIME; CIPROFLOXACIN; CLINDAMYCIN; COLISTIN; DAPTOMYCIN; DOXYCYCLINE; FLUCONAZOLE; GENTAMICIN; HYDROXYCHLOROQUINE; IMIPENEM; LINEZOLID; METHOTREXATE; OXACILLIN; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; TIGECYCLINE; TOBRAMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; BETA LACTAMASE INHIBITOR;

ACINETOBACTER BAUMANNII; ACUTE KIDNEY FAILURE; ADULT; AGED; ALCALIGENES FAECALIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM ISOLATE; CANDIDA PARAPSILOSIS; CARBAPENEMASE PRODUCING KLEBSIELLA PNEUMONIAE; CHOLESTASIS; CIRCUMORAL PARESTHESIA; DIABETES MELLITUS; DRUG WITHDRAWAL; FEMALE; HOSPITALIZATION COST; HUMAN; JOINT PROSTHESIS; KLEBSIELLA PNEUMONIAE; KNEE AMPUTATION; KNEE PROSTHESIS; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; MULTIDRUG RESISTANCE; MULTILOCUS SEQUENCE TYPING; NAUSEA; OSTEOARTHRITIS; POLYMERASE CHAIN REACTION; PROSTHESIS INFECTION; RELAPSE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; STREPTOCOCCUS PNEUMONIAE; SYNOVIAL FLUID; TERTIARY HEALTH CARE; TOTAL KNEE REPLACEMENT; TREATMENT OUTCOME; WOUND DRAINAGE; ADVERSE EFFECTS; BIOSYNTHESIS; CASE REPORT; CLASSIFICATION; CROSS INFECTION; DRUG EFFECTS; FATALITY; GENETICS; KLEBSIELLA INFECTIONS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MOLECULAR TYPING; OHIO; PROSTHESIS-RELATED INFECTIONS; TERTIARY CARE CENTER;

AGED; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; CROSS INFECTION; FATAL OUTCOME; FEMALE; HUMANS; JOINT PROSTHESIS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MOLECULAR TYPING; OHIO; PROSTHESIS-RELATED INFECTIONS; RETROSPECTIVE STUDIES; TERTIARY CARE CENTERS; TREATMENT OUTCOME;

EID: 84902074542     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2014.01.028     Document Type: Article

References (46)

1. Kurtz S., Mowat F., Ong K., Chan N., Lau E., Halpern M. Prevalence of primary and revision total hip and knee arthroplasty in the United States from 1990 through 2002. J Bone Joint Surg Am 2005, 87A:1487-1497.
2. Day J.S., Lau E., Ong K.L., Williams G.R., Ramsey M.L., Kurtz S.M. Prevalence and projections of total shoulder and elbow arthroplasty in the United States to 2015. J Shoulder Elbow Surg 2010, 19:1115-1120.
3. Kurtz S., Ong K., Lau E., Mowat F., Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am 2007, 89A:780-785.
4. Peel T.N., Dowsey M.M., Daffy J.R., Stanley P.A., Choong P.F., Buising K.L. Risk factors for prosthetic hip and knee infections according to arthroplasty site. J Hosp Infect 2011, 79:129-133.
5. Bozic K.J., Lau E., Kurtz S., Ong K., Rubash H., Vail T.P., Berry D.J. Patient-related risk factors for periprosthetic joint infection and postoperative mortality following total hip arthroplasty in Medicare patients. J Bone Joint Surg Am 2012, 94A:794-800.
6. Bozic K.J., Kurtz S.M., Lau E., Ong K., Vail T.P., Berry D.J. The epidemiology of revision total hip arthroplasty in the United States. J Bone Joint Surg Am 2009, 91A:128-133.
7. Kurtz S.M., Ong K.L., Schmier J., Zhao K., Mowat F., Lau E. Primary and revision arthroplasty surgery caseloads in the United States from 1990 to 2004. J Arthroplasty 2009, 24:195-203.
8. del Pozo J.L., Patel R. The challenge of treating biofilm-associated bacterial infection. Clin Pharmacol Ther 2007, 82:204-209.
9. Zmistowski B., Fedorka C.J., Sheehan E., Deirmengian G., Austin M.S., Parvizi J. Prosthetic joint infection caused by Gram-negative organisms. J Arthroplasty 2011, 26:104-108.
10. Hsieh P.H., Lee M.S., Hsu K.Y., Chang Y.H., Shih H.N., Ueng S.W. Gram-negative prosthetic joint infections: risk factors and outcome of treatment. Clin Infect Dis 2009, 49:1036-1043.
11. Aboltins C.A., Dowsey M.M., Buising K.L., Peel T.N., Daffy J.R., Choong P.F., Stanley P.A. Gram-negative prosthetic joint infection treated with debridement, prosthesis retention and antibiotic regimens including a fluoroquinolone. Clin Microbiol Infect 2011, 17:862-867.
12. Martinez-Pastor J.C., Munoz-Mahamud E., Vilchez F., Garcia-Ramiro S., Bori G., Sierra J., et al. Outcome of acute prosthetic joint infections due to Gram-negative bacilli treated with open debridement and retention of the prosthesis. Antimicrob Agents Chemother 2009, 53:4772-4777.
13. Kallen A.J., Srinivasan A. Current epidemiology of multidrug-resistant Gram-negative bacilli in the United States. Infect Control Hosp Epidemiol 2010, 31:S51-S54.
14. Rice L.B., Carias L.L., Hutton R.A., Rudin S.D., Endimiani A., Bonomo R.A. The KQ element, a complex genetic region conferring transferable resistance to carbapenems, aminoglycosides, and fluoroquinolones in Klebsiella pneumoniae. Antimicrob Agents Chemother 2008, 52:3427-3429.
15. Endimiani A., Carias L.L., Hujer A.M., Bethel C.R., Hujer K.M., Perez F., et al. Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing bla(KPC) in the United States. Antimicrob Agents Chemother 2008, 52:2680-2682.
16. Endimiani A., Hujer A.M., Perez F., Bethel C.R., Hujer K.M., Kroeger J., et al. Characterization of bla(KPC)-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. J Antimicrob Chemother 2009, 63:427-437.
17. Kumarasamy K.K., Toleman M.A., Walsh T.R., Bagaria J., Butt F., Balakrishnan R., et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010, 10:597-602.
18. Neuner E.A., Yeh J.Y., Hall G.S., Sekeres J., Endimiani A., Bonomo R.A., et al. Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Diagn Microbiol Infect Dis 2011, 69:357-362.
19. Perez F., Endimiani A., Ray A.J., Decker B.K., Wallace C.J., Hujer K.M., et al. Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination. J Antimicrob Chemother 2010, 65:1807-1818.
20. Patel G., Huprikar S., Factor S.H., Jenkins S.G., Calfee D.P. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008, 29:1099-1106.
21. Hennequin C., Aumeran C., Robin F., Traore O., Forestier C. Antibiotic resistance and plasmid transfer capacity in biofilm formed with a CTX-M-15-producing Klebsiella pneumoniae isolate. J Antimicrob Chemother 2012, 67:2123-2130.
22. Livermore D.M. Has the era of untreatable infections arrived?. J Antimicrob Chemother 2009, 64:i29-i36.
23. Diancourt L., Passet V., Verhoef J., Grimont P.A., Brisse S. Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates. J Clin Microbiol 2005, 43:4178-4182.
24. Tseng S.W., Chi C.Y., Chou C.H., Wang Y.J., Liao C.H., Ho C.M., et al. Eight years experience in treatment of prosthetic joint infections at a teaching hospital in Central Taiwan. J Microbiol Immunol Infect 2012, 45:363-369.
25. Hidron A.I., Edwards J.R., Patel J., Horan T.C., Sievert D.M., Pollock D.A., Fridkin S.K. Antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008, 29:996-1011.
26. Kitchel B., Rasheed J.K., Patel J.B., Srinivasan A., Navon-Venezia S., Carmeli Y., et al. Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother 2009, 53:3365-3370.
27. Cuzon G., Naas T., Truong H., Villegas M.V., Wisell K.T., Carmeli Y., et al. Worldwide diversity of Klebsiella pneumoniae that produces beta-lactamase bla(KPC-2) gene. Emerg Infect Dis 2010, 16:1349-1356.
28. Gupta N., Limbago B.M., Patel J.B., Kallen A.J. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011, 53:60-67.
29. Toubes E., Segreti J. Treatment options for orthopedic device-related infections. Curr Infect Dis Rep 2002, 4:433-438.
30. Zimmerli W., Ochsner P.E. Management of infection associated with prosthetic joints. Infection 2003, 31:99-108.
31. Livermore D.M., Warner M., Mushtaq S., Doumith M., Zhang J., Woodford N. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents 2011, 37:415-419.
32. Pogue J.M., Lee J., Marchaim D., Yee V., Zhao J.J., Chopra T., et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 2011, 53:879-884.
33. Costerton J.W. Introduction to biofilm. Int J Antimicrob Agents 1999, 11:217-221.
34. Trampuz A., Piper K.E., Jacobson M.J., Hanssen A.D., Unni K.K., Osmon D.R., et al. Sonication of removed hip and knee prostheses for diagnosis of infection. N Engl J Med 2007, 357:654-663.
35. Honda D.H., Adams H.G., Barriere S.L. Amikacin penetration into synovial-fluid during treatment of septic arthritis. Drug Intell Clin Pharm 1981, 15:284-286.
36. Tascini C., Menichetti F., Gemignani G., Palumbo F., Leonildi A., Tedeschi A., Piaggesi A. Clinical and microbiological efficacy of colistin therapy in combination with rifampin and imipenem in multidrug-resistant Pseudomonas aeruginosa diabetic foot infection with osteomyelitis. Int J Low Extrem Wounds 2006, 5:213-216.
37. Stanzani M., Tumietto F., Giannini M.B., Blanchi G., Nanetti A., Vianelli N., et al. Successful treatment of multi-resistant Pseudomonas aeruginosa osteomyelitis after allogeneic bone marrow transplantation with a combination of colistin and tigecycline. J Med Microbiol 2007, 56:1692-1695.
38. Rodvold K.A., Gotfried M.H., Cwik M., Korth-Bradley J.M., Dukart G., Ellis-Grosse E.J. Serum, tissue and body fluid concentrations of tigecycline after a single 100mg dose. J Antimicrob Chemother 2006, 58:1221-1229.
39. Qureshi Z.A., Paterson D.L., Potoski B.A., Kilayko M.C., Sandovsky G., Sordillo E., et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 2012, 56:2108-2113.
40. Pournaras S., Vrioni G., Neou E., Dendrinos J., Dimitroulia E., Poulou A., Tsakris A. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. Int J Antimicrob Agents 2011, 37:244-247.
41. Ji A.J., Saunders J.P., Amorusi P., Wadgaonkar N.D., O'Leary K., Leal M., et al. A sensitive human bone assay for quantitation of tigecycline using LC/MS/MS. J Pharm Biomed Anal 2008, 48:866-875.
42. Schintler M.V., Traunmueller F., Metzler J., Kreuzwirt G., Spendel S., Mauric O., et al. High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection. J Antimicrob Chemother 2009, 64:574-578.
43. Endimiani A., Patel G., Hujer K.M., Swaminathan M., Perez F., Rice L.B., et al. In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob Agents Chemother 2010, 54:526-529.
44. Souli M., Galani I., Boukovalas S., Gourgoulis M.G., Chryssouli Z., Kanellakopoulou K., et al. In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development. Antimicrob Agents Chemother 2011, 55:2395-2397.
45. Endimiani A., Hujer K.M., Hujer A.M., Pulse M.E., Weiss W.J., Bonomo R.A. Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2011, 55:82-85.
46. Livermore D.M., Mushtaq S., Warner M., Zhang J., Maharjan S., Doumith M., Woodford N. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2011, 55:390-394.